Landmark cancer clinical trial underway

The widely anticipated I-SPY 2 clinical trial was launched today by Biomarkers Consortium. This trial will involve as many as 800 patients in 20 US cancer centers, and is open to women with newly diagnosed locally advanced breast cancer. Many expect this trial to forever change the way new cancer drugs and therapies are tested.

On its face, the trial seems no different than any other, since it will test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone prior to undergoing surgery.

The difference is that the trial will investigate as many as a dozen different drugs from different manufacturers at one time, as opposed to a single agent. As results come in, doctors will have the flexibility to make changes to patient recruitment and to drop the ineffective drugs from the trial when it's clear they're not working.

In short, doctors will be able to personalize the therapies to individual patients and their tumors as the trial goes along, using biomarkers including genes and proteins to tailor the treatment to fit the tumor. This flexibility has the potential to save billions of dollars, and more importantly, to get effective therapies to market significantly sooner than ever before.

The trial's name, I SPY 2, is an acronym for Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Read more about it at http://ispy2.org.

By Ross Bonander

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap